Granisetron 1mg/1ml Concentrate For Solution For Infusion
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Granisetron 1mg/1ml Concentrate for Solution for Infusion
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1ml of concentrate contains 1mg granisetron (as granisetron hydrochloride). Each ampoule contains 1 ml of concentrate.
Excipients
Each 1ml of concentrate contains 3.5mg sodium.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Concentrate for solution for infusion or injection Sterile clear, colourless solution at pH 5.0-7.0.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Granisetron concentrate for solution for infusion is indicated in adults for the prevention and treatment of
- acute nausea and vomiting associated with chemotherapy and radiotherapy.
- post-operative nausea and vomiting.
Gransietron concentrate for solution for infusion is indicated for the prevention of delayed nausea and vomiting associated with chemotherapy and radiotherapy.
Granisetron concentrate for solution for infusion is indicated in children aged 2 years and above for the prevention and treatment of acute nausea and vomiting associated with chemotherapy.
4.2 Posology and method of administration
Posology
Chemo- and radiotherapy-induced nausea and vomiting (CINV and RINV)
Prevention (acute and delayed nausea)
A dose of 1-3 mg (10-40 qg/kg) of granisetron concentrate for solution for infusion should be administered either as a slow intravenous injection or as a diluted intravenous infusion 5 minutes prior to the start of chemotherapy. The solution should be diluted to 5 ml per mg.
Treatment (acute nausea)
A dose of 1-3 mg (10-40 qg/kg) of granisetron concentrate for solution for infusion should be administered either as a slow intravenous injection or as a diluted intravenous infusion and administered over 5 minutes. The solution should be diluted to 5 ml per mg. Further maintenance does of granisetron concentrate for solution for infusion may be administered at least 10 minutes apart. The maximum dose to be administered over 24 hours should not exceed 9 mg.
Combination with adrenocortical steroid
The efficacy of parental granisetron may be enhanced by an additional intravenous dose of an adrenocortical steroid e.g. by 8-20 mg dexamethasone administered before the start of the cytostatic therapy or by 250 mg methyl-prednisolone administered prior to the start and shortly after the end of the chemotherapy.
Paediatric population
The safety and efficacy of granisetron concentrate for solution for infusion in children aged 2 years and above has been well established for the prevention and treatment (control) of acute nausea and vomiting associated with chemotherapy and the prevention of delayed nausea and vomiting associated with chemotherapy. A dose of 10-40 qg/kg body weight (up to 3 mg) should be administered as an i.v. infusion, diluted in 10-30 ml infusion fluid and administered over 5 minutes prior to the start of chemotherapy. One additional dose may be administered within a 24 hour-period if required. This additional dose should not be administered until at least 10 minutes after the initial infusion.
Post-operative nausea and vomiting (PONV)
A dose of 1 mg (10 qg/kg) of granisetron concentrate for solution for infusion should be diluted to 5 ml and administered by slow intravenous injection. The maximum dose of granisetron to be administered over 24 hours should not exceed 3 mg.
For the prevention of PONV, administration should be completed prior to induction of anaesthesia.
Paediatric population
Currently available data are described in section 5.1, but no recommendation on a posology can be made. There is insufficient clinical evidence to recommend administration of the concentrate for solution for infusion to children in prevention and treatment of Post-operative nausea and vomiting (PONV).
Special populations Elderly and renal impairment
There are no special precautions required for its use in either elderly patients or those patients with renal or hepatic impairment.
Hepatic impairment
There is no evidence to date for an increased incidence of adverse events in patients with hepatic disorders. On the basis of its kinetics, whilst no dosage adjustment is necessary, granisetron should be used with a certain amount of caution in this patient group (see section 5.2).
Method of administration
Administration may be as either a slow intravenous injection (over 30 seconds) or as an intravenous infusion diluted in 20 to 50 ml infusion fluid and administered over 5 minutes.
4.3. Contraindications
Hypersensitivity to the active substance or to any of the excipients.
4.4. Special warnings and precautions for use
As granisetron may reduce lower bowel motility, patients with signs of sub-acute intestinal obstruction should be monitored following its administration.
As for other 5-HT3 antagonists, ECG changes including QT interval prolongation have been reported with granisetron. In patients with pre-existing arrhythmias or cardiac conduction disorders this might lead to clinical consequences. Therefore caution should be exercised in patients with cardiac co-morbidities, on cardiotoxic chemotherapy and/or with concomitant electrolyte abnormalities (see section 4.5).
Cross-sensitivity between 5-HT3 antagonists (e.g. dolasetron, ondansetron) has been reported.
4.5. Interaction with other medicinal products and other forms of interaction
As for other 5-HT3 antagonists, cases of ECG modifications including QT prolongation have been reported with granisetron. In patients concurrently treated with medicinal products known to prolong QT interval and/or which are arrhythmogenic, this may lead to clinical consequences (see section 4.4).
In studies in healthy subjects, no evidence of any interaction has been indicated between granisetron and benzodiazepines (lorazepam), neuroleptics (haloperidol) or anti-ulcer medicinal products (cimetidine). Additionally, granisetron has not shown any apparent medicinal product interaction with emetogenic cancer chemotherapies.
No specific interaction studies have been conducted in anaesthetised patients.
In human subjects, hepatic enzyme induction by phenobarbital has led to an increase in total plasma clearance (approx. 25%) following intravenous administration of granisetron.
In vitro studies have shown that ketoconazole may inhibit the metabolism of granisetron via the cytochrome P450 3A isoenzyme family. The clinical significance of this is unknown.
4.6. Pregnancy and lactation
Pregnancy
There is limited amount of data from the use of granisetron in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of granisetron during pregnancy.
Breastfeeding
It is unknown whether granisetron or its metabolites are excreted in human milk. As a precautionary measure, breast-feeding should not be advised during treatment with granisetron.
Fertility
In rats, granisetron had no harmful effects on reproductive performance or fertility.
4.7. Effects on ability to drive and use machines
Granisetron is not expected to impair the ability to drive or to use machines.
4.8 Undesirable effects
Summary of the safety profile
The most frequently reported adverse reactions for granisetron are headache and constipation, which may be transient. ECG changes including QT prolongation have been reported with granisetron (see sections 4.4 and 4.5).
Tabulated list of adverse reactions
The following table of listed adverse reactions is derived from clinical trials and postmarketing data associated with granisetron and other 5-HT3 antagonists.
Frequency categories are as follows:
Very common (<1/10)
Common (<1/100 to <1/10)
Uncommon (<1/1,000 to <1/100)
Rare (<1/10,000 to <1/1,000)
Very rare (<1/10,000)
|
Immune system disorders | |
|
Uncommon |
Hypersensitivity reactions e.g. anaphylaxis, urticaria |
|
Psychiatric disorders | |
|
Common |
Insomnia |
|
Nervous system disorders | |
|
Very common |
Headache |
|
Uncommon |
Extrapyramidal Reactions |
|
Cardiac disorders | |
|
Uncommon |
QT prolongation |
|
Gastrointestinal disorders | |
|
Very common |
Constipation |
|
Common |
Diarrhoea |
|
Hepatobiliary disorders | |
|
Common |
Elevated hepatic transaminases* |
|
Skin and subcutaneous tissue disorders | |
|
Uncommon |
Rash |
* Occurred at a similar frequency in patients receiving comparator therapy.
Description of selected adverse reactions
As for other 5-HT3 antagonists, ECG changes including QT prolongation have been reported with granisetron (see sections 4.4 and 4.5).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
4.9. Overdose
There is no specific antidote for granisetron. In the case of overdose with the tablets, symptomatic treatment should be given. Doses of up to 38.5 mg of granisetron as a single injection have been reported, with symptoms of mild headache but no other reported sequelae.
5. PHARMACOLOGICAL PROPERTIES
5.1. Pharmacodynamic properties
Pharmacotherapeutic group: Antiemetics and antinauseants, Serotonin (5-HT3)
antagonists.
ATC code: A04AA02
Neurological mechanisms, serotonin-mediated nausea and vomiting Serotonin is the main neurotransmitter responsible for emesis after chemo- or radiotherapy. The 5-HT3 receptors are located in three sites: vagal nerve terminals in the
gastrointestinal tract and chemoreceptor trigger zones located in the area postrema and the nucleus tractus solidarius of the vomiting centre in the brainstem. The chemoreceptor trigger zones are located at the caudal end of the fourth ventricle (area postrema). This structure lacks an effective blood-brain barrier, and will detect emetic agents in both the systemic circulation and the cerebrospinal fluid. The vomiting centre is located in the brainstem medullary structures. It receives major inputs from the chemoreceptor trigger zones, and a vagal and sympathetic input from the gut.
Following exposure to radiation or catotoxic substances, serotonin (5-HT) is released from enterochromaffine cells in the small intestinal mucosa, which are adjacent to the vagal afferent neurons on which 5-HT3 receptors are located. The released serotonin activates vagal neurons via the 5-HT3 receptors which lead ultimately to a severe
emetic response mediated via the chemoreceptor trigger zone within the area postrema.
Mechanism of action
Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites.
Chemotherapy- and radiotherapy-induced nausea and vomiting
Granisetron administered intravenously has been shown to prevent nausea and vomiting associated with cancer chemotherapy in adults and children 2 to 16 years of age.
Post-operative nausea and vomiting
Granisetron administered intravenously has been shown to be effective for prevention and treatment of post-operative nausea and vomiting in adults.
Pharmacological properties of granisetron
Interaction with neurotropic and other active substances through its activity on P 450-cytochrome has been reported (see section 4.5).
In vitro studies have shown that the cytochrome P450 sub-family 3A4 (involved in the metabolism of some of the main narcotic agents) is not modified by granisetron. Although ketaconazole was shown to inhibit the ring oxidation of granisetron in vitro, this action is not considered clinically relevant.
Although QT-prolongation has been observed with 5-HT3 receptors antagonists (see
section 4.4), this effect is of such occurrence and magnitude that it does not bear clinical significance in normal subjects. Nonetheless it is advisable to monitor both ECG and clinical abnormalities when treating patients concurrently with drugs known to prolong the QT (see section 4.5).
Paediatric use
Clinical application of granisetron was reported by Candiotti et al. A prospective, multicentre, randomised, double-blind, parallel-group study evaluated 157 children 2 to 16 years of age undergoing elective surgery. Total control of post-operative nausea and vomiting during the first 2 hours after surgery was observed in most patients.
5.2. Pharmacokinetic properties
Pharmacokinetics of the oral administration is linear up to 2.5-fold of the recommended dose in adults. It is clear from the extensive dose-finding programme that the anti-emetic efficacy is not unequivocally correlated with either administered doses or plasma concentrations of granisetron.
A fourfold increase in the initial prophylactic dose of granisetron made no difference in terms of either the proportion of patient responding to treatment or in the duration of symptoms control.
Distribution
Granisetron is extensively distributed, with a mean volume of distribution of approximately 3 l/kg. Plasma protein binding is approximately 65%.
Biotransformation
Granisetron is metabolised primarily in the liver by oxidation followed by conjugation. The major compounds are 7-OH-granisetron and its sulphate and glycuronide conjugates. Although antiemetic properties have been observed for 7-OH-granisetron and indazoline N-desmethyl granisetron, it is unlikely that these contribute significantly to the pharmacological activity of granisetron in man.
In vitro liver microsomal studies show that granisetron's major route of metabolism is inhibited by ketoconazole, suggestive of metabolism mediated by the cytochrome P450 3A subfamily (see section 4.5).
Elimination
Clearance is predominantly by hepatic metabolism. Urinary excretion of unchanged granisetron averages 12% of dose while that of metabolites amounts to about 47% of dose. The remainder is excreted in faeces as metabolites. Mean plasma half-life in patients by the oral and intravenous route is approximately 9 hours, with a wide intersubject variability.
Pharmacokinetics in special populations
Renal failure
In patients with severe renal failure, data indicate that pharmacokinetic parameters after a single intravenous dose are generally similar to those in normal subjects.
Hepatic impairment
In patients with hepatic impairment due to neoplasic liver involvement, total plasma clearance of an intravenous dose was approximately halved compared to patients without hepatic involvement. Despite these changes, no dosage adjustment is necessary (see section 4.2).
Elderly patients
In elderly subjects after single intravenous doses, pharmacokinetic parameters were within the range found for non-elderly subjects.
Paediatrics
In children, after single intravenous doses, pharmacokinetics are similar to those in adults when appropriate parameters (volume of distribution, total plasma clearance) are normalized for body weight.
5.3. Preclinical safety data
Preclinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, reproductive toxicity and genotoxicity. Carcinogenicity studies revealed no special hazard for humans when used in the recommended human dose. However, when administered in higher doses and over a prolonged period of time the risk of carcinogenicity cannot be ruled out.
A study in cloned human cardiac ion channels has shown that granisetron has the potential to affect cardiac repolarisation via blockade of HERG potassium channels. Granisetron has been shown to block both sodium and potassium channels, which potentially affects both depolarization and repolarization through prolongation of PR, QRS, and QT intervals. This data helps to clarify the molecular mechanisms by which some of the ECG changes (particularly QT and QRS prolongation) associated with this class of agents occur. However, there is no modification of the cardiac frequency, blood pressure or the ECG trace. If changes do occur, they are generally without clinical significance.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Sodium chloride
Sodium hydroxide (for pH adjustment)
Hydrochloric acid (for pH adjustment)
Water for injections
6.2 Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
6.3 Shelf life
3 years
The solution should be used immediately after dilution.
6.4 Special precautions for storage
Do not freeze.
Keep container in the outer carton in order to protect from light.
For storage conditions of the diluted medicinal product, see section 6.3.
6.5 Nature and contents of container
1 ml, clear glass type I ampoules; pack sizes: 1, 5 or 10 ampoules
1 ml, clear glass type I vials, sealed with rubber stopper and green cap; pack sizes: 1, 5 or 10 vials.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
Dilute before use. For single use only. Any unused portion should be discarded.
The diluted injections and infusions are to be inspected visually for particulate matter prior to administration. They should only be used if the solution is clear and free from particles.
Preparing the infusion
Children
To prepare the dose of 40 pg/kg, the appropriate volume is withdrawn and diluted with infusion fluid to a total volume of 10 to 30 ml. Any one of the following solutions may be used:
• 0.9% w/v sodium chloride solution
• 0.18% w/v sodium chloride and 4% w/v glucose solution
• 5% w/v glucose solution
• Hartmann's solution for injection
• sodium lactate solution or 10% mannitol solution.
No other diluents should be used.
Adults
To prepare a dose of 1mg, 1ml should be withdrawn from the ampoule and diluted to 5ml with 0.9% w/v sodium chloride solution. No other diluent should be used.
Intravenous infusions of granisetron should be prepared at the time of administration (see section 6.3).
Any unused product or waste material should be disposed of in accordance with local requirements.
7 MARKETING AUTHORISATION HOLDER
TEVA UK Limited, Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG, United Kingdom
8 MARKETING AUTHORISATION NUMBER(S)
PL 00289/1035
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
05/06/2008
10 DATE OF REVISION OF THE TEXT
14/04/2015